Joe Wiley

34 results

Amryt Pharma says its last day of trading on AIM will be January 10th next

Irish drug firm Amryt Pharma, which makes treatments for rare diseases, has announced plans to delist from the Alternative Investment Market (AIM) in (...)

Irish pharma group Amryt acquired US-headquartered Chiasma in August. Photograph: iStock

Irish pharmaceutical group Amryt has reported 14.6 per cent year-on-year revenue growth in the third quarter, with sales for the period reaching $56.5(...)

Amryt sells two drugs, Lomitapide – branded Lojuxta in the European Union – and Metreleptin, known as Myalepta, for treating cholesterol and similar conditions.

Irish rare disease specialist Amryt has reported record turnover in the second quarter of 2021 alongside upgraded full-year forecasts. Second quarter(...)

The drug Oleogel-S10 – also referred to as Filsuvez – is a gel which is a first therapy for patients with epidermolysis bullosa (EB). Photograph: iStock

Irish biotech company Amryt Pharma has been granted a priority review of a new drug application for its treatment for a rare medical condition known a(...)

Amryt sells two drugs Lomitapide – branded Lojuxta in the EU – and Metreleptin, known as Myalepta, for treating cholesterol and similar conditions.

Irish rare-disease drug group Amryt has acquired a US business in a landmark deal that expands its portfolio of medicines. The deal to buy US-headqua(...)

Amryt has asked for a  priority review, which can expedite the review process. Photograph: iStock

Irish biotech company Amryt Pharma has completed the rolling submission to US authorities of a New Drug Application (NDA) for a rare medical condition(...)

Dublin-headquartered Amryt listed on New York’s Nasdaq market last year. Photograph: iStock

Sales at Irish biopharmaceutical developer Amryt hit a record $182 million (€151 million) last year, the company said on Thursday. Amryt is developin(...)

In September, Amryt announced positive data from trials of a new drug for the rare skin condition epidermolysis bullosa (EB)

Dublin-based biopharmaceutical company Amryt Pharma said revenue rose 19 per cent to $49.3 million (€41.7 million) in the third quarter of 2020. The(...)

Swixx BioPharma is one of the largest agents for ethical pharmaceuticals serving research-based biopharma across central and eastern Europe. Photograph: Kiyoshi Ota/Bloomberg

Dublin pharma company Amryt said on Monday it has appointed Swiss pharma agent Swixx BioPharma to distribute its cholesterol drug Lojuxta across centr(...)

Blistering caused by epidermolysis bullosa (EB). Irish company Amryt  has developing a drug for the rare medical condition. Photograph: Dave Meehan

Shares in an Irish company developing a drug for a rare medical condition known as “butterfly skin” jumped over 50 per cent on Wednesday morning on th(...)

  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »